TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

July 31, 2003

Study Completion Date

December 31, 2005

Conditions
Tuberculosis, Pulmonary
Interventions
DRUG

moxifloxacin (with isoniazid, rifampin, pyrazinamide)

Trial Locations (23)

10016

New York University School of Medicine, New York

10032

Columbia University, New York

10037

Harlem Hospital Center, New York

20422

Washington DC Veterans Administration Medical Center, Washington D.C.

21231

Johns Hopkins University, Baltimore

30303

Emory University School of Medicine, Atlanta

37232

Veterans Administration Tennessee Valley Health Care System, Nashville

60141

Hines Vetrans Administration Medical Center, Hines

76104

University of North Texas Health Science Center, Fort Worth

77030

Houston Veterans Administration Medical Center, Houston

78284

Audie L Murphy Memorial Veterans Administration Medical Center, San Antonio

80204

Denver Public Health Department, Denver

90033

University of Southern California Medical Center, Los Angeles

92103

University of California at San Diego, San Diego

94110

University of California, San Francisco, San Francisco

98104

Seattle-King County Health Department, Seattle

02118

Boston University Medical Center, Boston

07107

New Jersey School of Medicine, Newark

V5Z 1L8

University of British Columbia, Vancouver

R3A 1R8

University of Manitoba, Winnipeg

H2X 2P4

Montreal Chest Institute, Montreal

Unknown

Nelson R Mandela School of Medicine, Durban

Makerere University Medical School, Kampala

All Listed Sponsors
lead

Centers for Disease Control and Prevention

FED

NCT00140309 - TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment | Biotech Hunter | Biotech Hunter